main
proteas
coronavirus
proteas
enterovirus
share
similar
activesit
architectur
uniqu
requir
glutamin
posit
substrat
uniqu
specif
essenti
role
viral
polyprotein
process
proteas
suitabl
target
develop
antivir
drug
order
obtain
nearequipot
broadspectrum
antivir
alphacoronavirus
betacoronavirus
enterovirus
pursu
structurebas
design
peptidomimet
aketoamid
inhibitor
main
proteas
six
crystal
structur
proteas
inhibitor
complex
determin
part
studi
compound
synthes
test
recombin
proteas
well
viral
replicon
virusinfect
cell
cultur
celltox
optim
substitu
aketoamid
prove
crucial
achiev
nearequipot
three
viru
genera
best
nearequipot
inhibitor
cyclopentylmethyl
cyclohexylmethyl
display
lowmicromolar
valu
enterovirus
alphacoronavirus
betacoronavirus
cell
cultur
cell
exhibit
threedigit
picomolar
activ
middl
east
respiratori
syndrom
coronaviru
chose
chemic
class
peptidomimet
aketoamid
assess
feasibl
achiev
antivir
drug
target
coronavirus
enterovirus
nearequipot
describ
structurebas
design
synthesi
evalu
inhibitori
activ
seri
compound
broadspectrum
activ
afford
studi
structureact
relationship
mainli
respect
posit
peptidomimet
one
compound
design
synthes
exhibit
excel
activ
merscov
result
effort
design
novel
aketoamid
broadspectrum
inhibitor
coronaviru
pro
enteroviru
pro
start
detail
analysi
follow
crystal
structur
unligand
target
enzym
sarscov
pro
ref
pdb
entri
bat
coronaviru
pro
surrog
close
relat
merscov
proteas
unpublish
work
xiao
et
al
pdb
entri
see
also
ref
pro
ref
pdb
entri
coxsackieviru
pro
unpublish
work
tan
et
al
pdb
entri
enteroviru
pro
ref
pdb
entri
enteroviru
pro
ref
pdb
entri
cours
present
studi
determin
crystal
structur
number
lead
aketoamid
compound
complex
sarscov
pro
pro
pro
support
design
improv
next
round
lead
optim
notabl
unexpect
differ
alphaand
betacoronaviru
pro
found
studi
structur
foundat
elucid
detail
subproject
involv
pro
hcov
volum
work
publish
separ
zhang
et
al
prepar
select
find
refer
main
proteas
newli
discov
coronaviru
link
wuhan
outbreak
respiratori
ill
ident
similar
aminoacid
sequenc
sarscov
pro
deriv
rna
genom
genbank
access
code
http
last
access
januari
result
report
inhibit
sarscov
like
also
appli
new
viru
seventeen
year
pass
sinc
outbreak
sever
acut
respiratori
syndrom
sar
yet
approv
treatment
infect
sar
coronaviru
sarscov
one
reason
despit
devast
consequ
sar
affect
patient
develop
antivir
drug
viru
would
commerci
viabl
view
fact
viru
rapidli
contain
reappear
sinc
result
emptyhand
middleeast
respiratori
syndrom
coronaviru
merscov
close
rel
sarscov
emerg
mer
character
sever
respiratori
diseas
quit
similar
sar
addit
frequent
caus
renal
failur
although
number
regist
mer
case
low
novemb
wwwwhoint
threat
merscov
pose
global
public
health
may
even
seriou
present
sarscov
relat
high
casefat
rate
compar
sar
fact
mer
case
still
accumul
seven
year
discoveri
viru
wherea
sar
outbreak
essenti
contain
within
month
potenti
humantohuman
transmiss
merscov
impress
demonstr
outbreak
south
korea
case
could
trace
back
singl
infect
travel
return
middl
east
sarslik
coronavirus
still
circul
bat
china
may
spill
human
popul
probabl
caus
current
outbreak
atyp
pneumonia
wuhan
link
seafood
anim
market
rna
genom
genbank
access
code
http
last
access
januari
new
betacoronaviru
featur
around
ident
sarscov
spite
consider
threat
pose
sarscov
relat
virus
well
merscov
obviou
number
case
far
warrant
commerci
develop
antivir
drug
target
mersand
sarscov
even
project
steadi
growth
number
mer
case
taken
account
possibl
solut
problem
could
develop
broadspectrum
antivir
drug
direct
major
viral
proteas
target
share
coronaviru
genera
well
relat
form
member
larg
genu
enteroviru
picornaviru
famili
among
member
genu
alphacoronaviru
human
coronavirus
hcov
ref
usual
caus
mild
respiratori
symptom
otherwis
healthi
individu
much
widespread
sarscov
merscov
therapeut
intervent
alphacoronavirus
indic
case
accompani
diseas
cystic
fibrosi
leukemia
certain
underli
medic
condit
enterovirus
includ
pathogen
caus
agent
outbreak
summer
flu
us
coxsackieviru
etiolog
agent
hand
foot
mouth
diseas
hfmd
coxsackieviru
caus
myocard
inflamm
human
rhinovirus
hrv
notori
known
lead
common
cold
also
capabl
caus
exacerb
asthma
copd
infect
virus
lead
seriou
outcom
thu
caus
poliolik
diseas
infect
proceed
asept
mening
enceph
pulmonari
edema
viral
myocard
acut
flaccid
paralysi
enterovirus
caus
clinic
diseas
much
frequent
coronavirus
antivir
drug
target
viru
famili
commerci
viabl
howev
enterovirus
differ
coronavirus
singlestrand
rna
genom
posit
polar
enterovirus
small
kb
wherea
coronavirus
featur
largest
rna
genom
known
date
kb
enterovirus
small
nake
particl
wherea
coronavirus
much
larger
envelop
nevertheless
relat
featur
share
two
group
virus
type
major
proteas
enterovirus
encod
region
genom
henc
proteas
design
pro
coronavirus
nonstructur
protein
main
proteas
pro
similar
enterovir
pro
cystein
proteas
vast
major
case
therefor
also
call
proteas
pro
first
crystal
structur
cov
pro
pro
ref
reveal
two
three
domain
enzym
togeth
resembl
chymotrypsinlik
fold
enterovir
pro
addit
ahel
domain
involv
dimer
proteas
fig
dimer
essenti
catalyt
activ
cov
pro
wherea
enterovir
pro
fig
function
monom
enterovir
pro
featur
classic
cy
gluasp
catalyt
triad
wherea
cov
pro
cy
dyad
yet
number
common
featur
share
two
type
proteas
particular
almost
absolut
requir
gln
posit
substrat
space
small
aminoacid
residu
gli
ala
ser
posit
encourag
us
explor
coronavir
pro
enterovir
pro
common
target
design
broadspectrum
antivir
compound
fact
known
human
proteas
specif
gln
cleavag
site
substrat
increas
attract
viral
target
hope
inhibitor
develop
show
toxic
versu
host
cell
inde
neither
enteroviru
pro
inhibitor
rupintrivir
develop
treatment
common
cold
caus
hrv
peptid
aldehyd
inhibitor
coronaviru
pro
recent
demonstr
lead
complet
recoveri
cat
normal
fatal
infect
felin
infecti
periton
viru
fipv
show
toxic
effect
human
cat
respect
figur
crystal
structur
sarscov
main
proteas
pro
ref
pdb
entri
coxsackiviru
proteas
pro
tan
et
al
unpublish
pdb
entri
catalyt
residu
indic
sphere
yellow
cy
blue
red
glu
coronaviru
pro
homodim
monom
compris
three
domain
b
structur
monomer
pro
resembl
ntermin
two
domain
sarscov
pro
structur
scale
imag
c
superimpost
residu
two
structur
involv
ligand
bind
superimposit
carri
align
catalyt
cyshi
pair
proteas
residu
sarscov
pro
shown
carbon
atom
cyan
pro
residu
orang
carbon
label
asterisk
proteas
target
studi
specif
cleav
peptid
bond
follow
residu
pro
uniqu
also
accept
cleavag
site
decid
use
ring
glactam
deriv
glutamin
henceforth
call
glnlactam
residu
aketoamid
see
scheme
moieti
found
good
mimic
glutamin
enhanc
power
inhibitor
probabl
compar
flexibl
glutamin
sidechain
rigid
lactam
lead
reduct
loss
entropi
upon
bind
target
proteas
synthet
effort
therefor
aim
optim
substitu
posit
aketoamid
synthesi
scheme
start
dianion
alkyl
nboc
glutam
acid
dimethyl
ester
bromoacetonitril
expect
alkyl
occur
highli
stereoselect
manner
give
exclus
product
follow
step
cyano
group
subject
hydrogen
insitu
cycliz
result
intermedi
afford
lactam
lactam
deriv
gener
remov
protect
group
hand
amid
acyl
chlorid
aamino
acid
methyl
ester
afford
intermedi
gave
rise
acid
via
alkalin
hydrolysi
key
intermedi
obtain
via
condens
lactam
deriv
ncap
amino
acid
ester
group
compound
reduc
correspond
alcohol
oxid
alcohol
product
dessmartin
periodinan
gener
aldehyd
follow
nucleophil
addit
isocyanid
gave
rise
compound
acid
condit
ahydroxyamid
prepar
remov
acetyl
group
compound
final
step
oxid
expos
alcohol
group
compound
gener
target
aketoamid
inhibitori
potenc
candid
aketoamid
evalu
purifi
recombin
sarscov
pro
pro
pro
pro
potent
compound
test
viral
replicon
sarscov
merscov
whole
rang
enterovirus
cell
culturebas
assay
tabl
supplementari
tabl
enabl
rapid
biosaf
screen
antivir
coronaand
enterovirus
noninfecti
replicationcompet
sarscov
replicon
use
along
subgenom
replicon
kind
gift
b
zhang
wuhan
china
easili
detect
report
activ
firefli
renilla
luciferas
replicon
previous
shown
reflect
viral
rna
synthesi
invitro
rna
transcript
enterovir
replicon
also
use
transfect
sarscov
replicon
contain
cmv
promot
plasmid
dna
use
transfect
initi
compound
design
synthes
carri
cinnamoyl
ncap
posit
benzyl
group
glutamin
lactam
glnlactam
benzyl
tabl
compound
show
good
mediocr
activ
recombin
sarscov
pro
compound
see
tabl
standard
deviat
pro
pro
surprisingli
complet
inact
pro
valu
mirror
sarscov
enteroviru
replicon
tabl
virusinfect
cell
cultur
result
obtain
also
good
mediocr
tabl
sarscov
vero
cell
merscov
cell
hcov
cell
host
enterovirus
rd
cell
hela
rh
cell
hela
rh
cell
cell
type
test
compound
gener
prove
nontox
select
indic
usual
tabl
crystal
structur
compound
complex
sarscov
pro
pro
pro
demonstr
aketocarbon
coval
link
activesit
cy
resp
proteas
fig
result
thiohemiket
r
configur
sarscov
pro
configur
pro
complex
reason
differ
oxygen
atom
thiohemiket
accept
hydrogen
bond
catalyt
proteas
rather
mainchain
amid
oxyanion
hole
sarscov
enzym
fig
b
c
inset
remark
succeed
obtain
crystal
structur
compound
complex
pro
even
though
inhibitori
effect
activ
enzym
fig
appar
compound
abl
bind
pro
absenc
peptid
substrat
compet
substrat
bind
site
due
low
affin
similar
observ
made
one
previou
studi
abl
determin
crystal
structur
complex
inact
michaelacceptor
compound
pro
ref
pdb
entri
figur
fit
compound
pink
carbon
atom
target
proteas
wheat
surfac
reveal
xray
crystallographi
complex
fo
fc
differ
densiti
contour
substratebind
site
sarscov
pro
transpar
surfac
select
sidechain
proteas
shown
green
carbon
atom
b
anoth
view
substrat
bind
site
sarscov
pro
note
lid
form
residu
neighbor
pocket
c
substratebind
site
pro
restrict
size
pocket
benzyl
group
compound
enter
deepli
site
note
pocket
also
cover
lid
centr
around
substratebind
site
pro
site
larg
cover
lid
crystal
structur
indic
fit
benzyl
group
pocket
cinnamoyl
cap
subsit
might
improv
see
fig
c
compound
synthes
attempt
howev
none
show
better
inhibitori
activ
major
recombin
proteas
compar
parent
compound
see
supplementari
result
investig
whether
residu
inhibitor
dispens
synthes
compound
compris
boc
glnlactam
benzyl
inact
purifi
proteas
replicon
test
show
activ
hela
rh
cell
crystal
structur
bound
pro
demonstr
group
enter
pocket
fig
conclus
although
probabl
room
improv
decid
maintain
origin
design
benzyl
cinnamoyl
focuss
improv
substituen
crystal
structur
sarscov
pro
pro
pro
complex
reveal
fundament
differ
pocket
coronaviru
proteas
enteroviru
proteas
caviti
cover
lid
former
open
one
side
latter
fig
bd
sarscov
pro
lid
form
helix
pro
loop
residu
lid
particular
case
sarscov
pro
thu
make
hydrophob
interact
substitut
inhibitor
wherea
interact
miss
enteroviru
pro
addit
lid
pocket
line
backwal
mainchain
atom
residu
cb
atom
sidewal
well
floor
sarscov
pro
pro
correspond
structur
element
mainchain
atom
residu
well
cb
atom
backwal
sidewal
floor
final
pro
form
backwal
residu
form
sidewal
constitut
floor
addit
pocket
differ
size
variou
proteas
sarscov
enzym
featur
largest
pocket
volum
embrac
residu
defin
sidewal
pocket
ligandfre
enzym
calcul
use
chimera
follow
pro
pocket
space
pro
far
smallest
pocket
three
enzym
free
space
accord
chimera
agreement
observ
good
fit
observ
benzyl
group
subsit
sarscov
pro
well
pro
fig
c
contrast
crystal
structur
complex
pro
compound
inact
demonstr
group
fulli
enter
pocket
enzym
restrict
size
site
fig
thu
properti
target
proteas
respect
pocket
defin
point
small
cover
lid
pro
larg
cover
sarscov
pro
larg
open
pro
comparison
crystal
structur
proteas
viru
genu
pro
alphacoronavirus
pdb
entri
pro
betacoronavirus
xiao
et
al
unpublish
pdb
entri
pro
enterovirus
pdb
entri
ensur
conclus
drawn
templat
structur
valid
famili
member
well
explor
sensit
pocket
toward
polar
substitu
para
posit
benzyl
group
synthes
compound
carri
group
substitut
abolish
almost
activ
sarscov
pro
compound
prove
inact
pro
well
wherea
valu
pro
pro
conclud
introduct
polar
fluorin
atom
compat
geometri
pocket
sarscov
pro
wherea
fluorin
accept
hydrogen
bond
pro
ref
probabl
also
pro
sarscov
pro
howev
carbonyl
group
residu
might
lead
repuls
fluorin
benzyl
group
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
tabl
aketoamideinduc
inhibit
subgenom
rna
synthesi
use
replicon
cellbas
assay
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
tabl
thiohemiket
r
configur
oxygen
accept
two
hydrogen
bond
oxyanionhol
amid
amid
oxygen
accept
hbond
sidechain
omit
clariti
b
substitu
fulli
enter
pocket
pro
much
smaller
less
plastic
correspond
pocket
sarscov
pro
cf
benzyl
therefor
bind
pocket
view
shown
probabl
reason
total
inact
compound
pro
small
size
pocket
due
replac
flexibl
sarscov
pro
rigid
enzym
stereochemistri
thiohemiket
r
sidechain
omit
clariti
c
bind
pro
stereochemistri
thiohemiket
group
accept
hydrogen
bond
wherea
amid
keto
group
accept
three
hbond
oxyanion
hole
residu
sidechain
omit
clariti
crystal
structur
complex
pro
show
short
inact
compound
lack
residu
group
insert
pocket
proteas
stereochemistri
thiohemiket
sidechain
omit
clariti
e
contrast
benzyl
isobutyl
group
small
flexibl
enough
enter
narrow
pocket
pro
thiohemiket
r
configur
sidechain
omit
clariti
f
spite
small
size
cyclopropylmethyl
sidechain
posit
tightli
bind
subsit
sarscov
pro
pocket
exhibit
pronounc
plastic
due
conform
flexibl
see
also
fig
stereochemistri
thiohemiket
sidechain
omit
clariti
group
appar
larg
fit
pocket
pro
replac
isobutyl
result
improv
activ
sarscov
pro
good
activ
pro
compar
inact
pro
howev
activ
decreas
differ
pro
interpret
result
smaller
substitu
still
interact
lid
particular
sarscov
pro
site
unabl
reach
backwal
pro
pocket
thu
absenc
lid
gener
suffici
enthalpi
bind
see
exampl
follow
trend
persist
among
inhibitor
smaller
substitu
even
though
sarscov
pro
pocket
larger
volum
enteroviru
pro
enzym
effici
inhibit
compound
carri
small
residu
make
hydrophob
interact
lid
floor
residu
replicon
even
sarscov
replicon
activ
rel
weak
tabl
agreement
replicon
data
prove
inact
rd
cell
show
limit
activ
hela
rh
cell
tabl
compar
good
activ
hela
rh
cell
unexpect
activ
hcov
cell
good
merscov
cell
excel
vero
cell
merscov
high
similarli
sarscov
vero
cell
tabl
manag
obtain
crystal
complex
pro
hcov
found
isobutyl
group
well
embed
pocket
fig
consequ
smaller
size
isobutyl
group
compar
benzyl
group
also
larger
conform
flexibl
allow
better
fit
bind
site
replac
residu
nbutyl
activ
follow
sarscov
pro
total
inact
pro
pro
pro
decreas
activ
case
sarscov
pro
total
inact
pro
indic
nbutyl
chain
long
pocket
proteas
wherea
slight
improv
pro
pro
probabl
consequ
extra
space
avail
long
flexibl
substitu
lack
lid
cover
enteroviru
pro
pocket
nbutyl
substitu
obvious
long
next
synthes
deriv
shorter
propargyl
ethinylmethyl
residu
compound
led
mediocr
activ
test
proteas
use
cyclopropyl
residu
compound
valu
even
higher
proteas
test
obvious
sidechain
requir
methylen
group
bposit
order
provid
necessari
flexibl
substitu
embed
pocket
realiz
addit
size
flexibl
substitu
may
import
factor
influenc
inhibitori
activ
introduc
flexibl
phenyl
ring
reduc
cyclohexylmethyl
deriv
exhibit
sarscov
pro
pro
pro
pro
thu
replac
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ment
phenyl
group
cyclohexyl
group
led
signific
improv
inhibitori
activ
recombin
sarscov
pro
dramat
improv
case
pro
even
pro
complet
inact
greatli
improv
albeit
still
weak
activ
observ
tabl
viral
replicon
perform
well
replicon
sarscov
tabl
virusinfect
cell
cultur
assay
tabl
exhibit
rd
cell
hela
cell
hcov
cell
surprisingli
low
interestingli
compound
prove
extrem
potent
merscov
cell
picomolar
even
vero
cell
merscov
sarscov
vero
cell
ie
best
activ
seen
pro
inhibitor
sarscov
type
cell
therapeut
index
hela
rh
cell
well
cell
rd
cell
point
decid
systemat
vari
size
ring
system
next
substitu
tri
cyclopropylmethyl
compound
show
good
activ
sarscov
pro
pro
poor
valu
pro
pro
tabl
shown
inhibit
sarscov
replicon
wherea
activ
replicon
poor
valu
tabl
replicon
result
mirror
antivir
activ
enterovirusinfect
cell
tabl
weak
weak
contrast
compound
inhibit
hcov
merscov
cell
respect
activ
latter
viru
vero
cell
poor
antisarscov
activ
vero
cell
tabl
next
analyz
crystal
structur
complex
sarscov
pro
compound
fig
cyclopropylmethyl
substitu
found
incorpor
deepli
pocket
make
hydrophob
interact
lid
floor
cb
backwal
spite
small
size
substitu
possibl
pocket
sarscov
pro
flexibl
enough
contract
enclos
moieti
tightli
plastic
express
conform
chang
residu
main
chain
sidechain
mainchain
conform
chang
connect
flip
peptid
torsion
angl
sidechain
chang
roughli
antiperiplanar
ap
synclin
sc
fig
conform
variabl
note
molecular
dynam
simul
crystal
structur
consequ
chang
sidechain
oxygen
accept
hydrogen
bond
mainchain
nh
residu
complex
see
fig
affin
pocket
pro
good
almost
ideal
match
size
requir
conform
chang
enzym
would
abl
undergo
replac
flexibl
rigid
pro
hand
dock
compound
crystal
structur
pro
reveal
cyclopropylmethyl
moieti
probabl
unabl
gener
suffici
free
energi
bind
miss
lid
larg
size
pocket
enteroviru
pro
therebi
explain
poor
inhibitori
activ
target
tabl
experi
viral
replicon
confirm
trend
although
valu
sarscov
surprisingli
high
tabl
cell
infect
merscov
compound
exhibit
vero
cell
wherea
sarscov
vero
cell
compound
larg
inact
rd
cell
inhibit
replic
two
hrv
subtyp
test
hela
rh
cell
valu
hela
cell
ie
therapeut
index
well
tabl
obvious
substitu
still
bit
small
enteroviru
proteas
next
step
test
cyclopentylmethyl
compound
turn
one
compound
accept
valu
test
enzym
sarscov
pro
pro
pro
pro
tabl
activ
replicon
tabl
cell
infect
hcov
merscov
show
merscov
vero
cell
sarscov
vero
cell
tabl
appear
far
best
compromis
compound
yet
individu
viral
enzym
follow
compound
prove
superior
cyclopropylmethyl
compound
sarscov
pro
isobutyl
compound
cyclopropylmethyl
pro
benzyl
cyclohexylmethyl
pro
pro
word
nearli
equipot
inde
compromis
therefor
view
surprisingli
good
antivir
activ
hcov
cell
relax
condit
univers
inhibitor
show
good
activ
recombin
pro
select
cyclohexylmethyl
lead
compound
develop
compound
exhibit
submicromolar
valu
pro
sarscov
pro
pro
tabl
well
similarli
low
valu
replicon
virus
tabl
cell
infect
merscov
perform
compound
excel
even
hcov
cell
sarscov
vero
cell
valu
respect
observ
tabl
also
enterovirusinfect
cell
cultur
compound
perform
well
valu
hela
rh
cell
select
valu
concern
activ
compound
rd
cell
valu
result
low
therapeut
index
hand
weak
toxic
detect
vero
cell
preliminari
pharmacokinet
test
compound
mice
indic
toxic
problem
publish
elsewher
describ
structurebas
design
synthesi
assess
cap
dipeptid
aketoamid
target
main
proteas
alphaor
betacoronavirus
well
proteas
enterovirus
crystallograph
analys
total
six
inhibitor
complex
three
differ
proteas
studi
found
aketoamid
warhead
coconh
steric
versatil
warhead
michael
acceptor
chchco
aldehyd
cho
featur
two
acceptor
hydrogen
bond
protein
name
aketo
oxygen
amid
oxygen
wherea
warhead
one
acceptor
variou
complex
hydroxi
group
oxyanion
thiohemiket
form
nucleophil
attack
activesit
cystein
residu
onto
aketo
carbon
accept
one
two
hydrogen
bond
mainchain
amid
oxyanion
hole
addit
amid
oxygen
inhibitor
accept
hydrogen
bond
catalyt
sidechain
altern
thiohemiket
interact
catalyt
residu
amid
oxygen
mainchain
amid
oxyanion
hole
depend
exact
interact
stereochemistri
thiohemiket
c
atom
would
differ
previous
observ
similar
differ
case
aldehyd
inhibitor
singl
interact
point
oxyanion
thiohemiacet
accept
hydrogen
bond
either
oxyanion
hole
catalyt
sidechain
result
differ
stereochemistri
thiohemiacet
carbon
aketoamid
aldehyd
react
revers
catalyt
nucleophil
proteas
wherea
michael
acceptor
form
irrevers
adduct
addit
better
match
hbond
donoracceptor
properti
catalyt
center
offer
two
hydrogenbond
acceptor
instead
one
aketoamid
anoth
big
advantag
aldehyd
bunsatur
ester
michael
acceptor
allow
easi
extens
inhibitor
probe
prime
specif
subsit
beyond
although
far
rare
explor
eg
ref
case
calpain
promin
aketoamid
drug
probabl
telaprivir
boceprivir
peptidomimet
inhibitor
hcv
proteas
help
revolution
treatment
chronic
hcv
infect
viral
cystein
proteas
aketoamid
occasion
describ
inhibitor
systemat
studi
carri
number
cap
dipeptidyl
aketoamid
describ
inhibitor
noroviru
proteas
optim
respect
substitu
wherea
isobutyl
case
occasion
benzyl
former
display
valu
one
order
magnitud
lower
latter
indic
pocket
noroviru
proteas
fairli
small
although
includ
noroviru
pro
studi
expand
target
rang
inhibitor
noroviru
probabl
realist
undertak
studi
underway
zeng
et
al
publish
seri
aketoamid
inhibitor
pro
author
mainli
studi
structureact
relationship
residu
found
small
alkyl
substitu
superior
larger
one
interestingli
also
report
sixmemb
dlactam
posit
led
time
higher
activ
compar
fivememb
glactam
time
kim
et
al
describ
seri
five
aketoamid
cyclopropyl
show
submicromolar
activ
two
hrv
strain
occasion
individu
aketoamid
report
literatur
inhibitor
enteroviru
proteas
coronaviru
main
proteas
singl
cap
dipeptidyl
aketoamid
cbzleuglnlactamcoconhipr
describ
inhibit
recombin
transmiss
gastroenter
viru
tgev
sarscov
pro
well
human
rhinoviru
polioviru
pro
onedigit
micromolar
rang
code
compound
show
poor
activ
cell
cultur
though
probabl
isobutyl
shown
isobutyl
sidechain
posit
inhibitor
small
complet
fill
pocket
pro
pro
among
seri
aldehyd
prior
et
al
describ
cap
tripeptidyl
aketoamid
show
valu
nanomolar
rang
hrv
pro
sarscov
pro
well
valu
hcov
cell
cultur
optim
compound
perform
toxic
data
report
compound
warhead
aketoamid
invitro
activ
coronaand
enterovirus
also
occasion
report
lee
et
al
describ
three
peptidyl
michael
acceptor
display
inhibitori
activ
pro
sarscov
hcov
well
pro
inhibitor
time
higher
enzym
compar
sarscov
pro
invari
isobutyl
leucin
compound
suggest
improv
might
possibl
addit
michael
acceptor
peptid
aldehyd
also
use
explor
inhibit
coronaviru
pro
well
enteroviru
pro
kim
et
al
report
dipeptidyl
aldehyd
bisulfit
adduct
exhibit
good
inhibitori
activ
isol
proteas
human
rhinoviru
polioviru
well
proteas
number
coronavirus
antivir
activ
cell
cultur
poor
probabl
due
isobutyl
leucin
seri
compound
use
glnlactam
glactam
throughout
substitu
proven
excel
surrog
glutamin
made
effort
optim
residu
compound
well
ncap
mainli
focuss
optim
substitu
nearli
studi
aim
discov
peptidomimet
inhibitor
coronaviru
pro
invari
isobutyl
leucin
residu
also
use
effort
design
compound
would
inhibit
enteroviru
pro
well
see
crystal
structur
earli
lead
compound
cinnamoylpheglnlactamcoconhbz
complex
pro
hcov
repres
alphacoronaviru
proteas
sarscov
betacov
well
pro
coxsackieviru
enteroviru
proteas
found
pocket
fundament
differ
shape
enzym
sarscov
pro
subsit
deep
hydrophob
pocket
truli
threedimension
shape
wall
groov
form
polypeptid
main
chain
around
residu
well
sidechain
catalyt
dyad
wherea
floor
form
lid
residu
particular
two
methionin
provid
import
interact
point
substitu
inhibitor
interact
mostli
hydrophob
charact
previous
describ
surpris
observ
carboxyl
aspart
residu
made
polar
interact
sulfur
atom
methionin
pocket
offer
mani
opportun
interact
featur
pronounc
plastic
substitu
isobutyl
leu
small
fill
pocket
entir
still
gener
suffici
bind
enthalpi
accordingli
pocket
sarscov
pro
toler
among
three
enzym
investig
term
versatil
accept
pocket
pro
replac
prolin
chang
accompani
signific
loss
flexibl
wherea
sidechain
sarscov
pro
found
accommod
conform
accord
steric
requir
substitu
prolin
less
flexibl
lead
much
smaller
space
entranc
pocket
consequ
substitu
hinder
penetr
deepli
pocket
wherea
smaller
flexibl
isobutyl
group
final
pro
pocket
lack
lid
ie
open
one
side
consequ
offer
less
interact
point
substitu
inhibitor
substitu
must
reach
backwal
pocket
form
order
creat
suffici
bind
energi
henc
larg
aromat
substitu
benzyl
favor
enteroviru
pro
introduc
fluoro
substitu
para
posit
group
lead
compound
observ
good
activ
enteroviru
pro
complet
inact
coronaviru
pro
see
tabl
compound
easili
explain
basi
crystal
structur
enteroviru
pro
fluorin
accept
hydrogen
bond
ref
wherea
coronaviru
pro
would
electrostat
repuls
mainchain
carbonyl
residu
agreement
rupintrivir
pfluorobenzyl
good
inhibitor
enterovir
pro
coronavir
main
proteas
predict
earlier
structurebas
inhibitor
optim
studi
achiev
major
improv
origin
lead
compound
systemat
vari
size
flexibl
compound
present
far
best
compromis
differ
requir
pocket
sarscov
pro
larg
cover
pro
small
cover
pro
larg
open
cyclopentylmethyl
satisfactori
broadspectrum
activ
proteas
test
howev
regard
antivir
activ
cell
cultur
inferior
cyclohexylmethyl
latter
compound
exhibit
good
inhibitori
activ
sarscov
pro
well
enteroviru
pro
perform
sarscov
enteroviru
replicon
convinc
low
micromolar
rang
data
antivir
activ
cell
cultur
correl
well
inhibitori
power
compound
recombin
proteas
well
repliconbas
assay
true
though
surprisingli
good
incellulo
activ
hcov
cell
also
correl
seem
hold
cell
test
antivir
activ
mani
compound
hcov
two
cell
type
found
lowor
submicromolar
valu
viru
cell
larg
inact
cell
shown
furthermor
compound
synthes
inact
vero
cell
shown
exhibit
good
excel
activ
viru
cell
previous
observ
similar
poor
antivir
activ
vero
cell
aketoamid
also
michael
acceptor
zhu
et
al
unpublish
work
similar
celltyp
depend
seen
antivir
activ
merscov
sarscov
wherea
inhibitor
exhibit
excel
activ
merscov
cell
host
cell
pm
inhibitori
activ
weaker
factor
vero
cell
use
hand
exhibit
excel
antimerscov
activ
human
lung
cell
ie
primari
target
cell
compound
act
therapeut
set
kupk
person
commun
test
antivir
activ
sarscov
exclus
vero
cell
valu
determin
compound
viru
onedigit
micromolar
rang
higher
best
compound
interestingli
rel
weaker
activ
even
inact
inhibitor
rna
virus
vero
cell
observ
independ
virolog
laboratori
leuven
leiden
thu
unlik
lack
activ
vero
cell
relat
problem
experiment
setup
preliminari
experi
replac
cinnamoyl
group
fluorophor
coumaryl
found
fluoresc
microscopi
much
inhibitor
appear
accumul
cell
compar
vero
cell
dl
rh
irina
majoul
unpublish
regardless
cell
system
suitabl
one
test
peptidomimet
antivir
compound
next
plan
test
smallanim
model
mer
coxsackievirusinduc
pancreat
parallel
aim
refin
experi
quantifi
accumul
peptidomimet
proteas
inhibitor
differ
hostcel
type
hope
find
explan
observ
celltyp
depend
work
demonstr
power
structurebas
approach
design
broadspectrum
antivir
compound
roughli
equipot
activ
coronavirus
enterovirus
observ
good
correl
inhibitori
activ
design
compound
isol
proteas
viral
replicon
virusinfect
cell
one
compound
exhibit
excel
antimerscov
activ
virusinfect
cell
high
similar
main
proteas
sarscov
novel
expect
exhibit
good
antivir
activ
new
coronaviru
well
crystal
recombin
product
purif
sarscov
pro
authent
n
c
termini
describ
detail
previous
use
amicon
membran
emd
millipor
purifi
sarscov
pro
concentr
buffer
mm
trishcl
mm
nacl
mm
dtt
mm
edta
ph
crystal
perform
equilibr
protein
mix
precipit
solut
reservoir
contain
polyethylen
glycol
peg
me
ph
use
vapor
diffus
sittingdrop
method
compound
dissolv
dmso
mm
mm
stock
concentr
respect
crystal
free
enzym
soak
cryoprotect
buffer
contain
mpd
peg
me
mm
ph
h
anoth
set
free
enzym
crystal
soak
anoth
cryoprotect
buffer
peg
mpd
me
glycerol
mm
ph
h
subsequ
crystal
fish
flashcool
liquid
nitrogen
prior
data
collect
crystal
pro
obtain
use
cocrystal
concentr
pro
incub
mm
h
follow
set
crystal
use
vapor
diffus
sittingdrop
method
equilibr
protein
mix
mother
liquor
reservoir
compos
lithium
sulfat
monohydr
sodium
citrat
tribas
dihydr
peg
ph
crystal
protect
cryobuff
contain
lithium
sulfat
monohydr
sodium
citrat
tribas
dihydr
peg
glycerol
mm
ph
flashcool
liquid
nitrogen
crystal
pro
gener
use
soak
method
sever
freeenzym
crystal
soak
cryoprotect
buffer
contain
lithium
sulfat
monohydr
sodium
citrat
tribas
dihydr
peg
glycerol
mm
ph
subsequ
soak
crystal
flashcool
liquid
nitrogen
freshli
prepar
pro
concentr
incub
mm
predissolv
dmso
room
tempatur
h
white
precipit
appear
mixtur
afterward
sampl
centrifug
x
g
min
supernat
subject
crystal
trial
use
follow
commerci
avail
kit
sigma
tm
sigmaaldrich
index
tm
peg
rx
tm
hampton
research
singl
rodlik
crystal
detect
index
tm
screen
condit
hexahydr
bistri
peg
ph
sigma
tm
screen
trishcl
peg
ph
crystal
optim
perform
use
vapordiffus
sittingdrop
method
pro
inhibitor
complex
mix
precipit
solut
equilibr
reservoir
contain
trishcl
ph
peg
vari
anoth
optim
screen
also
perform
differ
reservoir
trishcl
ph
rang
peg
vari
crystal
fish
differ
drop
protect
cryoprotect
solut
consist
mother
liquor
glycerol
subsequ
crystal
flashcool
liquid
nitrogen
diffract
data
collect
structur
elucid
refin
diffract
data
crystal
sarscov
pro
complex
collect
k
synchrotron
beamlin
psi
villigen
switzerland
use
pilatu
detector
dectri
diffract
data
set
sarscov
pro
crystal
compound
collect
k
beamlin
petra
iii
desi
hamburg
germani
use
type
detector
diffract
data
set
pro
complex
structur
complex
pro
collect
synchrotron
beamlin
bessi
berlin
germani
use
ccd
detector
rayon
data
set
process
program
xdsapp
scale
scala
suit
structur
sarscov
pro
determin
molecular
replac
structur
complex
sarscov
pro
pdb
entri
zhu
et
al
unpublish
search
model
employ
molrep
program
also
suit
complex
structur
pro
also
determin
molrep
use
search
model
structur
free
enzym
determin
us
lz
et
al
unpublish
complex
structur
pro
determin
base
search
model
freeenzym
structur
pdb
entri
tan
et
al
unpublish
geometr
restraint
compound
gener
use
jligand
built
fofc
differ
densiti
use
coot
softwar
refin
structur
perform
refmac
version
ref
buffer
contain
mm
trishcl
mm
nacl
mm
edta
mm
dtt
ph
use
enzymat
assay
two
substrat
cleavag
site
pro
pro
respect
indic
arrow
edan
edan
puriti
biosyntan
employ
fluoresc
reson
energi
transfer
fret
base
cleavag
assay
use
microtit
plate
dequench
edan
fluoresc
due
cleavag
substrat
catalyz
proteas
monitor
nm
excit
nm
use
fluoresc
spectrophotomet
biotek
curv
rel
fluoresc
unit
rfu
substrat
concentr
linear
substrat
beyond
indic
minim
influenc
innerfilt
effect
stock
solut
compound
prepar
dissolv
dmso
uv
absorpt
found
neglig
l
nm
interfer
fret
signal
innerfilt
effect
expect
determin
differ
proteas
specifi
final
concentr
sarscov
pro
pro
pro
separ
incub
inhibitor
variou
concentr
reaction
buffer
min
afterward
reaction
initi
ad
fret
peptid
substrat
final
concentr
final
volum
valu
determin
use
graphpad
prism
softwar
graphpad
measur
enzymat
activ
perform
triplic
present
mean
standard
deviat
sd
assess
inhibitori
activ
aketoamid
use
viral
replicon
virusinfect
cell
cell
virus
hepatocellular
carcinoma
cell
ref
deriv
constitut
express
rna
polymeras
ref
grown
dulbecco
modifi
minim
essenti
medium
dmem
supplement
mm
glutamin
penicillin
streptomycin
sulfat
fetal
calf
serum
growth
medium
mainten
medium
cell
addit
supplement
geneticin
sulfat
cell
use
enterovir
replicon
well
infect
experi
strain
nanci
enteroviru
except
infect
experi
human
rhabdomyosarcoma
cell
rd
brcr
strain
hela
rh
cell
human
rhinovirus
grown
mem
rega
medium
supplement
sodium
bicarbon
lglutamin
fetal
calf
serum
growth
medium
mainten
medium
kind
gift
volker
thiel
bern
switzerland
cultur
infect
experi
carri
describ
merscov
sarscov
infect
experi
vero
vero
cell
cultur
describ
previous
infect
vero
cell
merscov
strain
sarscov
infect
vero
cell
strain
low
multipl
infect
moi
done
describ
work
live
merscov
sarscov
perform
insid
biosafeti
cabinet
biosafeti
facil
leiden
univers
medic
center
netherland
viral
replicon
dnalaunch
sarscov
replicon
harbour
renilla
luciferas
report
directli
downstream
sarscov
replicas
polyproteincod
sequenc
urbani
strain
acc
context
bacteri
artifici
chromosom
bac
control
cmv
promot
describ
previous
pbacreprluc
apart
replicas
polyprotein
replicon
encod
follow
featur
region
ntr
ribozym
rz
bovin
growth
hormon
sequenc
structur
protein
n
subgenom
replicon
harbour
complet
viral
genom
capsidcod
sequenc
replac
firefli
photinu
pyrali
renilla
renilla
renifor
luciferas
gene
gener
provid
f
van
kuppeveld
b
zhang
respect
prepar
replicon
rna
transcript
plasmid
dna
linear
digest
sali
hindiii
new
england
biolab
respect
copi
rna
transcript
synthes
vitro
use
linear
dna
templat
rna
polymeras
largescal
rna
product
system
promega
accord
manufactur
recommend
transfect
cell
grown
plate
confluenc
x
cellswel
wash
ml
optimem
invitrogen
transfect
replicationcompet
replicon
optimem
final
volum
recommend
manufactur
invitrogen
roch
respect
transfect
mixtur
incub
h
overnight
prior
replac
growth
medium
contain
compound
investig
rnalaunch
transfect
enterovir
replicon
dmriec
use
transfect
reagent
accord
manufactur
recommend
invitrogen
experi
done
triplic
quadrupl
result
present
mean
valu
sd
test
inhibitori
activ
candid
compound
initi
perform
quick
assess
inhibitori
activ
candid
compound
toward
enterovir
coronavir
replicon
concentr
cell
compound
rel
power
nontox
concentr
assay
dosedepend
manner
estim
halfmaxim
effect
concentr
well
cytotox
describ
brief
differ
concentr
aketoamid
screen
experi
increas
concentr
determin
ad
growth
medium
replicontransfect
cell
twentyfour
hour
later
cell
wash
ml
phosphatebuff
salin
pb
optimem
invitrogen
lyse
ml
passiv
lysi
buffer
promega
room
temperatur
rt
min
freez
c
thaw
rt
cell
debri
remov
centrifug
x
g
min
supernat
assay
firefli
renilla
luciferas
activ
promega
biotrend
chemikalien
use
antho
luminesc
plate
reader
antho
microsystem
antivir
activ
compound
evalu
cytopath
effect
cpe
readout
assay
use
mt
innersalt
base
assay
briefli
h
prior
infect
cell
seed
plate
densiti
x
rd
cell
x
hela
rh
per
well
medium
supplement
fc
infect
medium
contain
mm
next
day
serial
dilut
compound
viru
inoculum
ad
readout
perform
day
post
infect
follow
medium
remov
mt
phenol
redfre
mem
ad
well
plate
incub
h
optic
densiti
nm
well
measur
microtit
plate
reader
saffir
tecan
od
valu
convert
percentag
control
calcul
logarithm
interpol
concentr
compound
result
protect
effect
virusinduc
cpe
condit
cell
morpholog
also
evalu
microscop
assay
merscov
sarscov
perform
previous
describ
brief
vero
vero
cell
seed
plate
densiti
vero
cell
vero
per
well
overnight
growth
cell
treat
indic
compound
concentr
dmso
solvent
control
infect
moi
final
volum
eagl
minim
essenti
medium
emem
contain
fc
mm
lglutamin
antibiot
cell
incub
two
day
cell
three
day
differ
cell
viabil
caus
virusinduc
cpe
compoundspecif
side
effect
analyz
use
celltit
aqueou
nonradioact
cell
prolifer
assay
promega
accord
manufactur
instruct
absorb
nm
measur
use
berthold
mithra
lb
plate
reader
berthold
cytotox
effect
caus
compound
treatment
alon
monitor
parallel
plate
contain
mockinfect
cell
probe
pdc
tt
pdu
g
pdu
gt
pdc
ta
pdc
metabion
standard
curv
prepar
use
serial
dilut
rna
isol
viru
stock
data
analys
use
graphpad
prism
valu
calcul
base
logist
statist
equat
parallel
qpcr
assay
inhibitor
cell
viabil
assay
perform
use
cell
viabil
reagent
thermofish
accord
manufactur
instruct
valu
calcul
use
inhibitor
versu
normal
respons
statist
equat
includ
proper
control
inhibitor
cell
determin
cell
toxic
candid
compound
celltit
one
solut
cell
prolifer
assay
mt
test
promega
celltit
glo
assay
kit
promega
nondestruct
cytotox
bioassay
toxilight
measur
releas
adenyl
kinas
damag
cell
lonza
rockland
cell
viabil
reagent
thermofish
use
determin
cytotox
effect
compound
toward
host
cell
accord
manufactur
recommend
chemic
synthesi
aketoamid
gener
procedur
reagent
purchas
commerci
sourc
use
without
purif
hsgf
mm
thick
use
analyt
thinlay
chromatographi
tlc
product
character
nmr
ms
spectra
h
nmr
spectra
record
instrument
chemic
shift
report
part
per
million
ppm
downfield
tetramethylsilan
proton
coupl
pattern
describ
singlet
doublet
triplet
quartet
q
multiplet
broad
br
mass
spectra
record
use
bruker
esi
iontrap
hct
ultra
hplc
spectra
record
shimadzu
corpor
shimpack
gist
three
solvent
system
methanolwat
methanol
hcooh
water
ammonia
water
puriti
determin
reversedphas
hplc
compound
test
biolog
synthesi
dimethyl
tertbutoxycarbonylamino
cyanomethyl
pentanedio
solut
nboclglutam
acid
dimethyl
ester
g
mmol
thf
ml
ad
dropwis
solut
lithium
bi
trimethylsilyl
amid
lhmd
thf
ml
nitrogen
result
dark
mixtur
stir
meanwhil
bromoacetonitril
ml
mmol
ad
dropwis
dianion
solut
period
h
keep
temperatur
reaction
mixtur
stir
addit
h
consumpt
reactant
confirm
tlc
analysi
reaction
quench
methanol
ml
acet
acid
ml
precool
thf
ml
ad
stir
min
cool
bath
remov
reaction
mixtur
allow
warm
room
temperatur
pour
brine
ml
organ
layer
concentr
purifi
flash
column
chromatographi
petroleum
etherethyl
acet
give
product
g
colorless
oil
h
nmr
mhz
j
hz
esim
mz
h
synthesi
methyl
tertbutoxycarbonylamino
propano
hydrogen
flask
place
compound
g
mmol
ml
chloroform
ml
methanol
addit
result
mixtur
stir
hydrogen
c
h
mixtur
filter
celit
remov
catalyst
naoac
g
mmol
ad
filtrat
result
mixtur
stir
c
h
reaction
quench
water
ml
suspens
extract
ethyl
acet
organ
layer
combin
dri
filter
lightbrown
filtrat
concentr
purifi
silica
gel
column
chromatographi
petroleum
etherethyl
acet
give
product
g
white
solid
h
nmr
br
synthesi
methyl
propano
compound
g
mmol
dissolv
ml
dichloromethan
dcm
ml
trifluoroacet
acid
tfa
ad
reaction
mixtur
stir
c
h
concentr
vacuo
get
colorless
oil
could
use
follow
step
without
purif
esim
mz
h
synthesi
methyl
nsubstitut
aminoacid
ester
gener
procedur
methyl
aminoacid
ester
hydrochlorid
mmol
dissolv
ml
acyl
chlorid
mmol
triethylamin
ml
mmol
ad
reaction
stir
h
c
reaction
mixtur
dilut
ml
wash
ml
satur
brine
ml
dri
solvent
evapor
product
obtain
white
solid
yield
could
use
next
step
without
purif
methyl
methyl
lphenylalanin
hydrochlorid
g
mmol
dissolv
ml
cinnamoyl
chlorid
g
mmol
triethylamin
ml
mmol
ad
reaction
stir
h
room
temperatur
reaction
mixtur
dilut
ml
wash
ml
satur
brine
ml
dri
solvent
evapor
product
obtain
white
solid
g
could
use
next
step
without
purif
synthesi
nsubstitut
amino
acid
gener
procedur
naoh
ml
ad
solut
compound
mmol
methanol
ml
reaction
stir
min
c
hcl
ad
reaction
solut
ph
reaction
mixtur
extract
ml
ml
organ
layer
wash
ml
brine
dri
solvent
evapor
crude
materi
purifi
silica
elut
mixtur
afford
product
yield
white
solid
synthesi
compound
gener
procedur
compound
mmol
dissolv
ml
dri
solut
equiv
g
bi
dimethylamino
methylen
pyridinium
hexafluorophosph
hatu
ad
reaction
stir
h
c
compound
mg
mmol
tea
ml
mmol
ad
reaction
reaction
stir
anoth
h
reaction
mixtur
pour
ml
water
aqueou
solut
extract
ml
ml
wash
ml
satur
brine
ml
dri
solvent
evapor
crude
materi
purifi
silica
elut
mixtur
give
product
yield
synthesi
alcohol
gener
procedur
compound
mmol
dissolv
methanol
ml
g
mmol
ad
ambient
condit
reaction
mixtur
stir
c
h
reaction
quench
water
ml
suspens
extract
ethyl
acet
organ
layer
combin
dri
filter
filtrat
evapor
dryness
could
use
next
step
without
purif
yield
synthesi
aldehyd
gener
procedur
compound
mmol
dissolv
dessmartin
periodinan
mg
mmol
mg
mmol
ad
result
mixtur
stir
c
h
mixtur
concentr
purifi
column
chromatographi
silica
gel
give
product
white
solid
yield
synthesi
compound
gener
procedur
compound
mmol
dissolv
acet
acid
g
mmol
isocyanid
mmol
ad
success
solut
reaction
stir
c
h
solvent
evapor
crude
materi
purifi
silica
elut
mixtur
give
product
synthesi
gener
procedur
naoh
ml
ad
solut
compound
mmol
methanol
ml
reaction
stir
c
h
consumpt
compound
confirm
tlc
analysi
hcl
ad
reaction
solut
ph
follow
solvent
evapor
gener
product
white
solid
could
use
directli
next
step
synthesi
gener
procedur
compound
dissolv
dessmartin
periodinan
mg
mmol
mg
mmol
ad
result
mixtur
stir
c
h
mixtur
concentr
purifi
column
chromatographi
silica
gel
give
aketoamid
light
yellow
solid
two
step
detail
result
variat
substitu
synthesi
aketoamid
supplement
tabl
inhibitori
activ
modif
viral
proteas
supplement
tabl
crystallograph
data
complex
viral
proteas
molecular
formula
string
biolog
data
csv
author
releas
atom
coordin
experiment
data
upon
articl
public
atom
coordin
includ
sarscov
pro
complex
compound
pro
complex
pro
complex
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
